Can oxidized LDL be elevated when urinary F2-isoprostanes and myeloperoxidase are not?

At age 64, discordant oxidative-stress biomarkers should be interpreted as signals from different biological compartments rather than as mutually validating—or excluding—tests. The proposed pattern is biologically coherent, although not directly quantified using standardized “high” and “normal” clinical cutoffs.

Clinical evidence

• Oxidized LDL (oxLDL) may be elevated despite non-elevated urinary F2-isoprostanes or plasma MPO. In healthy young adults, oxLDL had no overall correlation with other oxidative-stress biomarkers, while urinary isoprostanes showed distinct metabolic and antioxidant-enzyme associations.
• Intervention data similarly show nonparallel behavior: in metabolic syndrome, urinary isoprostanes decreased whereas the oxLDL/LDL ratio did not change significantly.
• Observational population and peripheral artery disease cohorts found no significant correlation between MPO and oxLDL, supporting possible biomarker discordance. These studies did not, however, quantify the exact threshold-defined pattern of high oxLDL with normal MPO and urinary F2-isoprostanes.

Mechanistic interpretation

• oxLDL reflects oxidative modification of apoB-containing lipoproteins—such as oxidized phospholipids and lipid–aldehyde adducts. Results depend substantially on the assay epitope and may be influenced by LDL burden, modification, and clearance.
• Urinary F2-isoprostanes principally reflect free-radical peroxidation of arachidonic acid, followed by release and urinary excretion. They are not a comprehensive readout of every oxidative pathway; renal handling, creatinine normalization, and assay method also affect interpretation.
• MPO is a neutrophil/monocyte-derived enzyme. Circulating MPO protein reflects enzyme abundance, not total oxidant injury, hypochlorous-acid production, or all lipid-peroxidation pathways.

Bottom line

• An isolated oxLDL elevation with non-elevated urinary F2-isoprostanes and MPO is plausible and moderately supported: it can indicate lipoprotein-focused oxidation without evidence of generalized arachidonic-acid lipid peroxidation or increased circulating leukocyte-derived MPO.